Denosumab: What's new?

Current Osteoporosis Reports

Volumn 9, Issue 1, 2011, Pages 12-19

  Bogado, Cesar E ^a   Zanchetta, Maria Belen ^a   Boailchuk, Juan A ^a   Massari, Fabio E ^a   Zanchetta, Jose R ^a  

^a Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

Bone mass; Denosumab; Osteoporosis treatment; Postmenopausal osteoporosis; RANKL; Vertebral fractures

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIANDROGEN; ANTIBIOTIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CREATININE; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; TRANSCRIPTION FACTOR PAX5; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE BIOPSY; BONE DEMINERALIZATION; BONE DENSITY; BONE EROSION; BONE MASS; BONE METASTASIS; BONE REMODELING; BONE STRUCTURE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER SURVIVAL; CELLULITIS; CHOLECYSTITIS; CHRONIC KIDNEY FAILURE; COMMUNICABLE DISEASE; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENDOCARDITIS; FRACTURE; FRAGILITY FRACTURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK PATIENT; HIP FRACTURE; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; IMMUNOMODULATION; INFECTION; JAW OSTEONECROSIS; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MORPHOMETRICS; NEOPLASM; OPPORTUNISTIC INFECTION; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PANCREATITIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND;

EID: 79551543868     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0040-1     Document Type: Article

References (27)

1. R Heaney 2003 Remodeling and skeletal fragility Osteoporos Int 14 Suppl 5 S12 S15
2. P Pivonka J Zimak DW Smith 2008 Model structure and control of bone remodeling: a theoretical study Bone 43 249 263 1:CAS:528:DC%2BD1cXosVOit74%3D 10.1016/j.bone.2008.03.025 18514606
3. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 1:CAS:528:DyaK1cXivVyhtrg%3D 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
4. H Hsu DL Lacey CR Dunstan, et al. 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 96 3540 3545 1:CAS:528: DyaK1MXjslCitL8%3D 10.1073/pnas.96.7.3540 10097072 (Pubitemid 29168945)
5. J Li I Sarosi XQ Yan, et al. 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc Natl Acad Sci USA 97 1566 1571 1:CAS:528:DC%2BD3cXhsFCrsL4%3D 10.1073/pnas.97.4.1566 10677500 (Pubitemid 30118482)
6. WS Simonet DL Lacey CR Dunstan, et al. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 1:CAS:528:DyaK2sXislCgtLc%3D 10.1016/S0092-8674(00)80209-3 9108485
7. LC Hofbauer M Schoppet 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 282 490 495 10.1001/jama.292.4.490 (Pubitemid 38988958)
8. MS Ominsky PJ Kostenuik P Cranmer, et al. 2007 The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys Osteoporos Int 18 1073 1082 1:CAS:528:DC%2BD2sXntVOlsrk%3D 10.1007/s00198-007-0363-7 17384898 (Pubitemid 47020009)
9. PJ Bekker DL Holloway AS Rasmussen, et al. 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066 1:CAS:528: DC%2BD2cXlvFWrtr0%3D 10.1359/JBMR.040305 15176987 (Pubitemid 41110556)
10. MR McClung EM Lewiecki SB Cohen, et al. 2006 Denosumab in post menopausal women with low bone mineral density N Engl J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 10.1056/NEJMoa044459 16495394 (Pubitemid 43290920)
11. EM Lewiecki PD Miller MR McClung, et al. 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 10.1359/jbmr.070809 17708711 (Pubitemid 351229299)
12. PD Miller MA Bolognese EM Lewiecki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy. A randomized blinded phase 2 clinical trial Bone 43 222 229 1:CAS:528:DC%2BD1cXosVOitrk%3D 10.1016/j.bone.2008.04.007 18539106 This discusses the 4-year extension of the phase 2 denosumab clinical trial data showing the rapid offset effects on BMD and BTM on discontinuation of denosumab and maintenance of the response to denosumab upon rechallenge
13. Miller PD, Bolognese MA, Lewiecki EM, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. Available from: http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=1cf516b5-29be-4edf-b1ed-7fa92b4f2031 [last accessed 01 September 2010]
14. HG Bone MA Bolognese CK Yuen, et al. 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 1:CAS:528:DC%2BD1cXntFamtrg%3D 10.1210/jc.2007-2814 18381571 (Pubitemid 351831529)
15. SR Cummings J San Martin MR McClung, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655 This is the pivotal clinical trial showing a significant reduction in vertebral, hip, and nonvertebral fracture risk with denosumab in postmenopausal women with osteoporosis
16. JP Brown RL Prince C Deal, et al. 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 1:CAS:528:DC%2BD1MXht1yrtbc%3D 10.1359/jbmr.0809010 18767928 This phase 3, multicenter, double-blind study compared the efficacy and safety of denosumab with alendronate in postmenopausal women with low bone mass, showing that denosumab induced significantly larger gains in BMD and greater reduction in BTMs compared with alendronate
17. DL Kendler C Roux CL Benhamou, et al. 2010 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy J Bone Miner Res 25 72 81 1:CAS:528:DC%2BC3cXksl2lu7c%3D 10.1359/jbmr.090716 19594293
18. • Reid I, Miller P, Brown J, et al. Effects of denosumab on bone histomorphometry: The freedom and stand studies. J Bone Miner Res 2010 Jun 8. [Epub ahead of print]. This is the first description of bone histomorphometry with denosumab use confirming that this agent produces a potent and sustained inhibition of bone turnover and maintains normal bone microarchitecture without evidence of adverse effects on mineralization.
19. E Seeman PD Delmas DA Hanley, et al. 2010 Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate J Bone Miner Res 25 1886 1894 10.1002/jbmr.81 20222106
20. G Block HG Bone L Fang, et al. 2010 A single dose study of denosumab in patients with various degrees of renal impairment Am J Kid Dis 55 A46 10.1053/j.ajkd.2010.02.064
21. SB Cohen RK Dore NE Lane, et al. 2008 Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis Rheum 58 1299 1309 1:CAS:528:DC%2BD1cXms1ehu70%3D 10.1002/art.23417 18438830 (Pubitemid 351705919)
22. MR Smith B Egerdie N Hernández Toriz, et al. 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 745 755 1:CAS:528:DC%2BD1MXhtVWls7rF 10.1056/NEJMoa0809003 19671656
23. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer J Clin Oncol 26 4875 4882 1:CAS:528:DC%2BD1cXhtlGitrzO 10.1200/JCO.2008.16.3832 18725648
24. K Fizazi MA Carducci MR Smith, et al. 2010 A randomized phase III trial of denosumab versus zolendronic acid in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 28 Suppl 18S
25. S Vadhan-Raj DH Henry R von Moos, et al. 2010 Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): analysis from a phase III randomized trial J Clin Oncol 28 Suppl 15S
26. A Stopeck JJ Body Y Fujiwara, et al. 2009 Denosumab versus zolendronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase III study Eur J Can Suppl 7 2 10.1016/S1359-6349(09)72028- 2
27. A Toulis D Anastasilakis 2010 Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab Osteoporosis Int 21 1963 1964 1:STN:280:DC%2BC3cflsVGjtg%3D%3D 10.1007/s00198-009-1145-1